Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 27 Carcinoma, Hepatocellular 24 Small Cell Lung Carcinoma 18 Lung Neoplasms 15 Neoplasms 13 Breast Neoplasms 9 Colorectal Neoplasms 7 Carcinoma, Renal Cell 7 Squamous Cell Carcinoma of Head and Neck 6 Melanoma 6 Uterine Cervical Neoplasms 5 Urinary Bladder Neoplasms 5 Triple Negative Breast Neoplasms 5 Prostatic Neoplasms 5 Neoplasm Metastasis 5 Carcinoma, Transitional Cell 5 Sarcoma 4 Glioblastoma 4 Stomach Neoplasms 3 Solid Tumors 3 Sarcoma, Alveolar Soft Part 3 Ovarian Neoplasms 3 Mesothelioma, Malignant 3 Liver Neoplasms 3 Extensive Stage Lung Small Cell Carcinoma 3 Endometrial Neoplasms 3 Carcinoma, Neuroendocrine 3 Carcinoma 3 Treatment-Refractory Solid Tumors 2 Small Cell Lung Cancer Extensive Stage 2

Interventions

atezolizumab 1 alectinib 1 Vemurafenib 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Genomic Instability × atezolizumab × 90 days × Clear all

NCT02314481 2026-05-04

DARWINII

University College, London

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Genomic Instability

Data powered by HemOnc (CC BY 4.0) Colophon ⚡